Avadel pharmaceuticals posts q3 loss per share of $0.24

Avadel pharmaceuticals reports third quarter 2019 financial results and raises revenue guidance for fy2019.q3 loss per share $0.24.q3 revenue $14.2 million versus $19.8 million.sees fy 2019 revenue $55 million.avadel pharmaceuticals - cash, cash equivalents and marketable securities as of sept 30 totaled $72.5 million.avadel pharmaceuticals - fda is reviewing an nda for a fourth hospital product, av001, with a pdufa target action date of dec 15.
AVDL Ratings Summary
AVDL Quant Ranking